2025 Conditions Data Epilepsy 
Cannabis Law Report
SEPTEMBER 13, 2021
Positive data from this important study would significantly advance MYMD-1’s potential to become a blockbuster drug for inflammation and aging.”. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. is the master regulator of inflammation, MYMD-1’s function as a TNF-?
Cannabis Law Report
NOVEMBER 16, 2021
Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
SMPL
MAY 26, 2020
CBD industry will be worth $16 billion by 2025. And though a few outliers responded well to CBD alone, GW’s data showed that for relieving pain and inflammation, helping with sleep and alleviating seizures and spasms, most patients got the most benefit from an equal mix of CBD and THC — a drug the company called Sativex.
Puff Puff Post
DECEMBER 28, 2018
An official study is aimed to conclude in July of 2019, where we’ll see all the data which comes forth. They aren’t geared towards treating the condition specifically, and rather focus on reducing side-effects from the disorder like anxiety and insomnia. 60% of children afflicted with anxiety had improvements in their condition.
Cannabis Law Report
OCTOBER 17, 2019
Some of the potential health benefits associated with THC and CBD, with and without the high, respectively, include reducing chronic pain such as from migraines or cancer, alleviating anxiety, reducing inflammation, and helping treat conditions such as epilepsy, PTSD, and glaucoma. billion in 2025, according to Grandview Research.
Expert insights. Personalized for you.
52 
Let's personalize your content